Linagliptin
| Status | Pipeline |
| Development phase | |
| Therapeutic cat. | Diabetics |
| Polymorphic form | Mix A&B |
| CAS No. | 668270-12-0 |
| Reference Product | |
| Injectable Form | |
| EU DMF readiness |  |
| CEP | |
| CHINESE DMF | |
| JAPANESE DMF | |
| KOREAN DMF | |
| CANADIAN DMF | |
| CADIFA | |
| US DMF readiness | |
| OEB No. | |
| Samples |
Drug description
Linagliptin is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. linagliptin is not for treating type 1 diabetes.Linagliptin may also be used for purposes not listed in this medication guide.
Polpharma API
- Wide portfolio for diabetes (Empagliflozin, Dapagliflozin, Sitagliptin)
- The highest API purity granted thanks to quasi-cristallization of the intermediate
- Fast process due to improved isolation and processability of the intermediate
Disclaimer
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s). Based on exemption under art. 5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Dapagliflozin (amorphous), Linagliptin, Rivaroxaban and Ticagrelor, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulationare met.
